PL3115372T3 - Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania - Google Patents

Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Info

Publication number: PL3115372T3
Authority: PL; Poland
Prior art keywords: fusion proteins; lysosomal enzyme; targeted therapeutic; enzyme fusion; therapeutic lysosomal
Prior art date: 2012-11-27

Application number

PL16182420T

Other languages

English (en)

Inventor

Mika Aoyagi-Scharber

Teresa Margaret Christianson

Melita Dvorak-Ewell

Daniel Wendt

Shinong Long

Jonathan Lebowitz

Daniel Solomon Gold

Original Assignee

Biomarin Pharmaceutical Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-27

Filing date

2013-11-27

Publication date

2019-09-30

2013-11-27 Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.

2019-09-30 Publication of PL3115372T3 publication Critical patent/PL3115372T3/pl

Links

102000004190 Enzymes Human genes 0.000 title 1
108090000790 Enzymes Proteins 0.000 title 1
102000037865 fusion proteins Human genes 0.000 title 1
108020001507 fusion proteins Proteins 0.000 title 1
230000002132 lysosomal effect Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)

PL16182420T 2012-11-27 2013-11-27 Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania PL3115372T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261730378P	2012-11-27	2012-11-27
US201361788968P	2013-03-15	2013-03-15
EP16182420.6A EP3115372B1 (en)	2012-11-27	2013-11-27	Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
PCT/US2013/072287 WO2014085621A1 (en)	2012-11-27	2013-11-27	Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
EP13802834.5A EP2925776B1 (en)	2012-11-27	2013-11-27	Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Publications (1)

Publication Number	Publication Date
PL3115372T3 true PL3115372T3 (pl)	2019-09-30

Family

ID=49753532

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13802834T PL2925776T3 (pl)	2012-11-27	2013-11-27	Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania
PL16182420T PL3115372T3 (pl)	2012-11-27	2013-11-27	Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL13802834T PL2925776T3 (pl)	2012-11-27	2013-11-27	Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

Country Status (26)

Country	Link
US (9)	US9376480B2 (pl)
EP (2)	EP2925776B1 (pl)
JP (2)	JP6831176B2 (pl)
KR (4)	KR20230054482A (pl)
CN (1)	CN104822701B (pl)
AR (1)	AR093626A1 (pl)
AU (1)	AU2013352184B2 (pl)
BR (1)	BR112015012152B1 (pl)
CA (1)	CA2892146A1 (pl)
CL (1)	CL2015001371A1 (pl)
CY (1)	CY1122555T1 (pl)
DK (2)	DK3115372T3 (pl)
ES (2)	ES2729997T3 (pl)
HR (2)	HRP20181351T1 (pl)
HU (2)	HUE039334T2 (pl)
IL (3)	IL238824B (pl)
LT (1)	LT3115372T (pl)
MX (2)	MX367024B (pl)
PL (2)	PL2925776T3 (pl)
PT (2)	PT3115372T (pl)
RS (1)	RS58916B1 (pl)
RU (1)	RU2680581C2 (pl)
SI (1)	SI3115372T1 (pl)
TW (2)	TWI626250B (pl)
WO (1)	WO2014085621A1 (pl)
ZA (1)	ZA201503509B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0912225A2 (pt)	2008-05-07	2018-03-20	Zystor Therapeutics, Inc.	peptídeos de direcionamento lisossomais e usos dos mesmos
PL2925776T3 (pl)	2012-11-27	2018-11-30	Biomarin Pharmaceutical Inc.	Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania
CA3209821A1 (en) *	2013-05-15	2014-11-20	Regents Of The University Of Minnesota	Adeno-associated virus mediated gene transfer to the central nervous system
EP3185889B1 (en)	2014-08-11	2020-07-15	Shire Human Genetic Therapies, Inc.	Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
US20180303877A1 (en) *	2014-09-25	2018-10-25	The General Hospital Corporation	Cell-based targeted delivery of pseudonomas exotoxin
WO2016065319A1 (en) *	2014-10-24	2016-04-28	Shire Human Genetic Therapies, Inc.	Lysosomal targeting of enzymes, and uses thereof
TWI752907B (zh) *	2015-05-08	2022-01-21	美商拜奧馬林製藥公司	用於治療cln2疾病之tpp1調配物及方法
ES2971045T3 (es)	2015-07-06	2024-06-03	Regeneron Pharma	Moléculas multiespecíficas de unión a antígeno y usos de las mismas
CN108474788A (zh)	2015-11-06	2018-08-31	生物马林药物股份有限公司	用于检测中和溶酶体酶的摄取的抗体或其它因子的基于细胞的测定
IL261246B2 (en) *	2016-02-24	2023-03-01	Biomarin Pharm Inc	Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses
IL305449B2 (en)	2016-04-15	2026-01-01	Univ Pennsylvania	Gene therapy for the treatment of mucocutaneous type ii diabetes
CL2016003282A1 (es)	2016-12-21	2017-08-18	Univ Chile	Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018226861A1 (en)	2017-06-07	2018-12-13	Regeneron Pharmaceuticals, Inc.	Compositions and methods for internalizing enzymes
BR112020005249A2 (pt)	2017-09-22	2020-09-24	The Trustees Of The University Of Pennsylvania	terapia de gene para tratar mucopolissacaridose tipo ii
PE20210347A1 (es)	2017-10-02	2021-02-25	Denali Therapeutics Inc	Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
CA3090519A1 (en)	2018-02-07	2019-08-15	Regeneron Pharmaceuticals, Inc.	Methods and compositions for therapeutic protein delivery
JP2021517168A (ja) *	2018-03-09	2021-07-15	アブロバイオ，インコーポレーテッド	パーキンソン病を処置するための組成物及び方法
JP7749322B2 (ja) *	2018-04-30	2025-10-06	アミカスセラピューティックスインコーポレイテッド	遺伝子治療構築物及び使用方法
KR20250140631A (ko)	2018-05-17	2025-09-25	리제너론 파마슈티칼스 인코포레이티드	항-cd63 항체, 콘쥬게이트, 및 이의 용도
WO2019233842A1 (en)	2018-06-08	2019-12-12	F. Hoffmann-La Roche Ag	Peptidic linker with reduced post-translational modification
AR116624A1 (es)	2018-10-10	2021-05-26	Amicus Therapeutics Inc	Composiciones de polipéptidos estabilizados por enlaces disulfuro y métodos de uso
WO2020102667A2 (en) *	2018-11-16	2020-05-22	Asklepios Biopharmaceutical, Inc.	Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
AU2020361703A1 (en) *	2019-10-10	2022-04-28	Amicus Therapeutics, Inc.	Variant IGF2 constructs
CN115379850A (zh)	2019-12-24	2022-11-22	裘美娜治疗公司	再生性多肽及其用途
WO2021183895A1 (en)	2020-03-13	2021-09-16	Biomarin Pharmaceutical Inc.	Treatment of fabry disease with aav gene therapy vectors
AU2022298470A1 (en)	2021-06-21	2024-02-01	Juvena Therapeutics, Inc.	Regenerative polypeptides and uses thereof
WO2022271981A2 (en)	2021-06-23	2022-12-29	Lycia Therapeutics, Inc.	Bifunctional compounds containing igf-2 polypeptides
CN117343197A (zh) *	2021-10-15	2024-01-05	中山大学	重组融合抗体
US20250339384A1 (en) *	2023-01-27	2025-11-06	Regeneron Pharmaceuticals, Inc.	Modified rhabdovirus glycoproteins and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5206161A (en)	1991-02-01	1993-04-27	Genentech, Inc.	Human plasma carboxypeptidase B
AUPN674895A0 (en)	1995-11-23	1995-12-14	Women's And Children's Hospital	Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
US6217552B1 (en)	1999-03-01	2001-04-17	Coaxia, Inc.	Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
DE10035433C2 (de)	2000-07-20	2002-07-18	Tuma Wolfgang	Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
WO2003102583A1 (en)	2002-05-29	2003-12-11	Symbiontics, Inc.	Targeted therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US20040005309A1 (en)	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
ES2300439T3 (es)	2001-04-30	2008-06-16	Zystor Therapeutics , Inc.	Reconocimiento subcelular de proteinas terapeuticas.
AU2002362930A2 (en)	2001-10-16	2003-04-28	Zystor Therapeutics, Inc.	Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en)	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US7485314B2 (en)	2002-05-06	2009-02-03	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Induction of antigen specific immunologic tolerance
ES2371072T3 (es)	2003-06-12	2011-12-27	Eli Lilly And Company	Proteínas de fusión análogas de glp-1.
US7442372B2 (en)	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh)	2004-02-10	2011-10-26	生物马林医药公司	酸性α-糖苷酶及其片段
AU2006220709B2 (en)	2005-03-04	2012-09-06	Biogen Ma Inc.	Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
BRPI0912225A2 (pt)	2008-05-07	2018-03-20	Zystor Therapeutics, Inc.	peptídeos de direcionamento lisossomais e usos dos mesmos
US8697654B2 (en) *	2008-12-18	2014-04-15	E I Du Pont De Nemours And Company	Peptide linkers for effective multivalent peptide binding
US9029530B2 (en)	2009-01-02	2015-05-12	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
EP2475376B1 (en)	2009-06-17	2016-03-30	BioMarin Pharmaceutical Inc.	Formulations for lysosomal enzymes
WO2011163562A2 (en)	2010-06-25	2011-12-29	Amcor Limited	Oxygen scavenging system for a container
CN103269709A (zh) *	2010-06-25	2013-08-28	夏尔人类遗传性治疗公司	Sanfilippo综合症类型B的治疗
US9409950B2 (en) *	2010-12-23	2016-08-09	Biogen Ma Inc.	Linker peptides and polypeptides comprising same
WO2012122042A2 (en) *	2011-03-04	2012-09-13	Shire Human Genetic Therapies, Inc.	Peptide linkers for polypeptide compositions and methods for using same
US8580922B2 (en)	2011-03-04	2013-11-12	Shire Human Genetic Therapies, Inc.	Peptide linkers for polypeptide compositions and methods for using same
WO2012122477A1 (en) *	2011-03-10	2012-09-13	Novozymes A/S	Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
PL2925776T3 (pl)	2012-11-27	2018-11-30	Biomarin Pharmaceutical Inc.	Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania

2013
- 2013-11-27 PL PL13802834T patent/PL2925776T3/pl unknown
- 2013-11-27 ES ES16182420T patent/ES2729997T3/es active Active
- 2013-11-27 KR KR1020237012007A patent/KR20230054482A/ko not_active Ceased
- 2013-11-27 JP JP2015544209A patent/JP6831176B2/ja active Active
- 2013-11-27 SI SI201331450T patent/SI3115372T1/sl unknown
- 2013-11-27 PT PT16182420T patent/PT3115372T/pt unknown
- 2013-11-27 AU AU2013352184A patent/AU2013352184B2/en active Active
- 2013-11-27 PT PT138028345T patent/PT2925776T/pt unknown
- 2013-11-27 KR KR1020157017224A patent/KR102262882B1/ko active Active
- 2013-11-27 RS RS20190585A patent/RS58916B1/sr unknown
- 2013-11-27 HU HUE13802834A patent/HUE039334T2/hu unknown
- 2013-11-27 DK DK16182420.6T patent/DK3115372T3/da active
- 2013-11-27 BR BR112015012152-7A patent/BR112015012152B1/pt active IP Right Grant
- 2013-11-27 MX MX2015006644A patent/MX367024B/es active IP Right Grant
- 2013-11-27 HU HUE16182420A patent/HUE043679T2/hu unknown
- 2013-11-27 CN CN201380061935.4A patent/CN104822701B/zh active Active
- 2013-11-27 DK DK13802834.5T patent/DK2925776T3/en active
- 2013-11-27 AR ARP130104367A patent/AR093626A1/es active IP Right Grant
- 2013-11-27 EP EP13802834.5A patent/EP2925776B1/en active Active
- 2013-11-27 CA CA2892146A patent/CA2892146A1/en active Pending
- 2013-11-27 KR KR1020217017007A patent/KR102385392B1/ko active Active
- 2013-11-27 KR KR1020227011416A patent/KR102521039B1/ko active Active
- 2013-11-27 EP EP16182420.6A patent/EP3115372B1/en active Active
- 2013-11-27 ES ES13802834.5T patent/ES2679374T3/es active Active
- 2013-11-27 PL PL16182420T patent/PL3115372T3/pl unknown
- 2013-11-27 HR HRP20181351TT patent/HRP20181351T1/hr unknown
- 2013-11-27 RU RU2015125491A patent/RU2680581C2/ru active
- 2013-11-27 TW TW102143329A patent/TWI626250B/zh active
- 2013-11-27 MX MX2019009191A patent/MX377150B/es active IP Right Grant
- 2013-11-27 TW TW107114660A patent/TWI711632B/zh active
- 2013-11-27 US US14/092,336 patent/US9376480B2/en active Active
- 2013-11-27 LT LTEP16182420.6T patent/LT3115372T/lt unknown
- 2013-11-27 WO PCT/US2013/072287 patent/WO2014085621A1/en not_active Ceased
2015
- 2015-05-14 IL IL238824A patent/IL238824B/en active IP Right Grant
- 2015-05-19 ZA ZA2015/03509A patent/ZA201503509B/en unknown
- 2015-05-20 CL CL2015001371A patent/CL2015001371A1/es unknown
- 2015-10-14 US US14/883,169 patent/US9845346B2/en active Active
- 2015-10-14 US US14/883,203 patent/US9834588B2/en active Active
- 2015-10-14 US US14/883,193 patent/US9834587B2/en active Active
- 2015-10-14 US US14/883,211 patent/US9771408B2/en active Active
2017
- 2017-08-28 US US15/688,438 patent/US10301369B2/en active Active
2018
- 2018-11-13 IL IL262976A patent/IL262976B/en active IP Right Grant
2019
- 2019-04-08 US US16/378,163 patent/US11254725B2/en active Active
- 2019-05-17 HR HRP20190918TT patent/HRP20190918T1/hr unknown
- 2019-06-06 CY CY20191100600T patent/CY1122555T1/el unknown
- 2019-07-24 JP JP2019136013A patent/JP6913719B2/ja active Active
2020
- 2020-02-23 IL IL272854A patent/IL272854B/en unknown
2022
- 2022-01-10 US US17/572,018 patent/US20220127326A1/en not_active Abandoned
2025
- 2025-01-17 US US19/030,525 patent/US20250388644A1/en active Pending

Also Published As

Publication number	Publication date
SI3115372T1 (sl)	2019-08-30
MX2019009191A (es)	2019-10-09
MX367024B (es)	2019-08-02
US20250388644A1 (en)	2025-12-25
US20190225666A1 (en)	2019-07-25
US9376480B2 (en)	2016-06-28
CA2892146A1 (en)	2014-06-05
JP2016505539A (ja)	2016-02-25
JP6913719B2 (ja)	2021-08-04
MX377150B (es)	2025-03-07
CL2015001371A1 (es)	2015-10-09
JP6831176B2 (ja)	2021-02-17
TWI626250B (zh)	2018-06-11
US20160031963A1 (en)	2016-02-04
PL2925776T3 (pl)	2018-11-30
AU2013352184A1 (en)	2015-06-04
US20160039900A1 (en)	2016-02-11
US20170355744A1 (en)	2017-12-14
HRP20181351T1 (hr)	2018-11-02
US20160031965A1 (en)	2016-02-04
US20140161788A1 (en)	2014-06-12
BR112015012152B1 (pt)	2023-04-25
IL272854A (en)	2020-04-30
US9834587B2 (en)	2017-12-05
MX2015006644A (es)	2015-08-10
US9771408B2 (en)	2017-09-26
WO2014085621A1 (en)	2014-06-05
JP2019206556A (ja)	2019-12-05
ES2729997T3 (es)	2019-11-07
AU2013352184B2 (en)	2018-05-31
US10301369B2 (en)	2019-05-28
US9834588B2 (en)	2017-12-05
DK3115372T3 (da)	2019-06-11
EP3115372A1 (en)	2017-01-11
CY1122555T1 (el)	2021-01-27
TWI711632B (zh)	2020-12-01
PT3115372T (pt)	2019-06-12
HUE043679T2 (hu)	2019-09-30
IL238824B (en)	2018-11-29
ES2679374T3 (es)	2018-08-24
EP2925776B1 (en)	2018-05-30
IL262976B (en)	2020-02-27
KR20220047892A (ko)	2022-04-19
US11254725B2 (en)	2022-02-22
HK1216026A1 (en)	2016-10-07
US20220127326A1 (en)	2022-04-28
TW201431884A (zh)	2014-08-16
US9845346B2 (en)	2017-12-19
IL262976A (en)	2018-12-31
LT3115372T (lt)	2019-06-25
ZA201503509B (en)	2016-11-30
KR102521039B1 (ko)	2023-04-12
RU2015125491A (ru)	2017-01-10
RS58916B1 (sr)	2019-08-30
RU2680581C2 (ru)	2019-02-22
HUE039334T2 (hu)	2018-12-28
PT2925776T (pt)	2018-07-30
US20160031964A1 (en)	2016-02-04
TW201827468A (zh)	2018-08-01
KR20230054482A (ko)	2023-04-24
KR102385392B1 (ko)	2022-04-11
IL238824A0 (en)	2015-06-30
IL272854B (en)	2021-07-29
KR20150088317A (ko)	2015-07-31
HRP20190918T1 (hr)	2019-09-20
DK2925776T3 (en)	2018-09-03
CN104822701B (zh)	2018-09-21
EP3115372B1 (en)	2019-03-06
AR093626A1 (es)	2015-06-17
BR112015012152A2 (pt)	2017-08-15
KR102262882B1 (ko)	2021-06-10
CN104822701A (zh)	2015-08-05
KR20210070389A (ko)	2021-06-14
EP2925776A1 (en)	2015-10-07

Publication	Publication Date	Title
IL272854B (en)	2021-07-29	Medicinal lysosomal enzyme chimeric proteins and their uses
IL281148A (en)	2021-04-29	New and used KIF5B-RET fusion compounds
PT3489254T (pt)	2022-12-30	Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
IL236809A0 (en)	2015-03-31	Interleukin-10 fusion proteins and their use
IL279676A (en)	2021-03-01	Recombinant proteins and therapeutic uses
IL236933A0 (en)	2015-03-31	Interleukin-2 fusion proteins and their use
PT3434775T (pt)	2020-04-08	Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
EP2785837A4 (en)	2015-07-01	TARGETED ENZYMATIC COMPOUNDS AND ITS USES
IL229753A0 (en)	2014-01-30	Proteins that release relaxin and their use
SG11201502455TA (en)	2015-05-28	Fgfr3 fusion gene and pharmaceutical drug targeting same
IL222382A0 (en)	2012-12-31	Robo1-fc fusion protein and use thereof for treating tumours
EP2880050A4 (en)	2016-05-11	NOVEL ENZYMES, ENZYME COMPONENTS AND USES THEREOF
SG11201403852UA (en)	2014-09-26	Fused pyrroledicarboxamides and their use as pharmaceuticals
EP2718432A4 (en)	2015-01-07	NUCLEASE FUSION PROTEIN AND USES THEREOF
GB2523211B (en)	2020-03-18	MCT protein inhibitor-related prognostic and therapeutic methods
EP2536741A4 (en)	2013-08-21	THERAPY TARGETING FUSIONS OF GENES
AU2012901619A0 (en)	2012-05-10	Fusion Proteins and Use Thereof
AU2011902431A0 (en)	2011-07-07	Fusion Proteins and Use Thereof
AU2011905077A0 (en)	2011-12-22	Radiotracers and Therapeutic Agents